Skip to content

Study · Animal study (in vivo) · mouse and rat · 2004

3 results

[Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice].

Eremin KO, Saransaari P, Oja S, Raevskiĭ KS

Eksperimental'naia i klinicheskaia farmakologiia1 Mar 2004Cited by 2 (Europe PMC)

PMID15188751 (opens in a new tab)PepBankPUB-15188751
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Sprague-Dawley rats, semax given before D-amphetamine produced a greater peak of striatal dopamine than D-amphetamine alone.

    In plain wordsIn rats, semax given before amphetamine gave a higher peak of dopamine in the brain than amphetamine alone.

    Peptide
    Semax
    Outcome
    IncreaseExtracellular dopamine peak in striatum
    Study

    ratn: not reported in source

    Sprague-Dawley rat striatum, microdialysis
    Comparator
    D-amphetamine alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Preliminary (20 min before D-amphetamine) administration of semax resulted in a greater peak of DA concentration (p < 0.05)
    1 context sentence
    Summary · context
    D-amphetamine (5 mg/kg) induced a sharp increases in the DA level (up to 20 pmole/ml) 20-40 min after treatment and reduced the extracell DHPAA content to 30% of the basal level for a prolonged time (over the entire experimental period).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Sprague-Dawley rats, semax given before D-amphetamine produced a more pronounced drop in extracellular DHPAA than D-amphetamine alone.

    In plain wordsIn rats, semax given before amphetamine caused a bigger drop in a dopamine breakdown product than amphetamine alone.

    Peptide
    Semax
    Outcome
    DecreaseExtracellular DHPAA level in striatum
    Study

    ratn: not reported in source

    Sprague-Dawley rat striatum, microdialysis
    Comparator
    D-amphetamine alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Preliminary (20 min before D-amphetamine) administration of semax resulted in a greater peak of DA concentration (p < 0.05) and a more pronounced drop in DHPAA level (p < 0.01) as compared to the effects produced by the psychostimulant alone.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In C57BL/6 mice, semax given with D-amphetamine increased locomotor activity more than D-amphetamine alone.

    In plain wordsIn mice, semax given with amphetamine raised movement more than amphetamine alone.

    Peptide
    Semax
    Outcome
    IncreaseLocomotor activity with D-amphetamine
    Study

    mousen: not reported in source

    C57BL/6 mice, behavioral test
    Comparator
    D-amphetamine alone
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    0.6 mg/kgAs given in this study (mouse).

    Measurements

    locomotor activity
    261%
    semax 0.6 mg/kg plus D-amphetamine 2 mg/kg
    locomotor activity
    182%
    D-amphetamine 2 mg/kg alone

    Source sentences

    Summary
    In behavioral tests on C57/BL6 mice, D-amphetamine (2 mg/kg) increased the locomotor activity to a level of 182% (p < 0.01). Simultaneous introduction of semax (0.6 mg/kg) and D-amphetamine (2 mg/kg) led to a more pronounced increase in the locomotor activity of mice (261%, p < 0.01).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.